EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P43
Within normal range
vs 5Y Ago
-1.2x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-86.82%
2024-8001.87%
202397.61%
2022-33.63%
2021-239.62%
202074.00%
2019-158.51%
2018-6.68%
2017-25.61%
2016-262.09%